2cureX is an European biotechnology company that helps physicians to select an individual drug therapy for their cancer patients. They have laboratories in Copenhagen, Denmark, and in Hamburg, Germany. 2cureX has extensive knowledge of functional test systems (Functional Precision Medicine) for prediction of patient sensitivity to various approved drug treatments. 2cureX has developed the CE-IVD registered IndiTreat® (Individual Treatment) test. It establishes thousands of 3D micro-tumors that are similar to the patient’s tumor and identifies the treatment that most effectively kills the patient’s tumor and the treatment to which the patient is resistant. Immediately after the test, the patient can be offered the selected treatment. IndiTreat® is being clinically validated in clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine and will be further developed in DECIDER. Read more on the 2curex website.
